Medical Research Agency Awarded Adamed Pharma in the “Enterprise” Category

On 5 December, during the conference entitled “Medical Research Agency – An Impulse for the Development of Science, Health and Innovation”, the Medical Research Agency President’s Awards “Medicine of Tomorrow” were presented. Adamed Pharma received the award in the “Enterprise” category.

The cornerstone of any business is investment, which is the foundation for growth, operations and strengthening of the company’s potential. Therefore, one of the key pillars of Adamed Pharma’s growth and operations is investment and innovation. For years, Adamed Pharma has been investing in both the development of research facilities and infrastructure through the expansion of the Production and Logistics Centre in Pabianice. Over the past two decades, Adamed Pharma has spent nearly PLN 2 billion on investment and R&D activities. The company plans to invest another billion in this area by 2025.

“Grants from the Medical Research Agency are an important part of co-financing of activities carried out by Adamed Pharma’s scientific team. But it also confirms that both the works on completely new solutions as well as those on added value in drugs not already covered by a patent are characterised by innovation. And we, as a Polish drug manufacturer, introduce innovative solutions that serve patients and also ensure drug security,” said Karolina Czekaj, PhD, Director for Corporate Finance and Governance, Adamed Pharma S.A.

The conference was also a space for international experts to discuss global trends in clinical trials, the needs and opportunities for the development of this sector, as well as potential for cooperation between the public sector and business. The event is an opportunity to wrap up the activities of the Medical Research Agency to date, with a special focus on selected research projects that support the Polish healthcare system.